Chester County News and Community Website
PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) reported recently updated clinical data for its PBFT02 therapy in frontotemporal dementia and said it has initiated a strategic review process following …
Passage Bio Reports Trial Data, Reviews Strategic Options Read More
WASHINGTON, D.C. — Federal health officials are investing up to $139.4 million in new research to accelerate the development of mental health treatments, including emerging therapies such as digital tools, …
$139M Mental Health Push Aims to Speed New Treatments Read More
WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) will present clinical results from its QTORIN™ rapamycin program at the ISSVA World Congress 2026 in Philadelphia, with data from Phase 3 …
Palvella to Present QTORIN Study Data at ISSVA 2026 Conference Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) said it will present Phase 1 clinical data for its investigational drug Teverelix at the American Association of Clinical Endocrinology Annual Meeting, …
Medicus Pharma to Present Phase 1 Data on Teverelix at AACE 2026 Read More
WASHINGTON, D.C. — Federal regulators are pushing thousands of companies and researchers to disclose missing clinical trial results, warning that gaps in reporting may distort how drugs and medical products …
FDA Presses Firms to Report Missing Clinical Trial Results Read More PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) said it will present new Phase 1 clinical data on Teverelix, its investigational long-acting gonadotropin-releasing hormone antagonist, at the American Association of …
Medicus Pharma to Present Phase 1 Teverelix Data at Endocrinology Meeting Read More
MALVERN, PA — YPrime recently launched a new Participant Hub within its electronic clinical outcome assessment platform aimed at improving patient engagement and retention in clinical trials.
YPrime Launches eCOA Participant Hub to Improve Trial Engagement Read More WILMINGTON, DE — Inhibikase Therapeutics Inc. (Nasdaq: IKT) has enrolled the first patient in its Phase 3 clinical trial evaluating IKT-001 for pulmonary arterial hypertension, advancing development of the drug …
Inhibikase Enrolls First Patient in Phase 3 PAH Trial Read More
PHILADELPHIA, PA — Medicus Pharma Ltd. (Nasdaq: MDCX) recently submitted an updated Phase 2 clinical study design to the U.S. Food and Drug Administration for Teverelix, an investigational treatment aimed …
Medicus Submits Phase 2 Study Design for Teverelix to FDA Read More
WILMINGTON, DE — AstraZeneca reported that its drug combination including IMFINZI and IMJUDO, used with lenvatinib and transarterial chemoembolization, improved progression-free survival in patients with unresectable liver cancer eligible for …
AstraZeneca Trial Shows Improved Outcomes in Liver Cancer Study Read More